Association of HLA genetic risk burden with disease phenotypes in multiple sclerosis

JAMA Neurology

Volumn 73, Issue 7, 2016, Pages 795-802

  Isobe, Noriko ^a   Keshavan, Anisha ^a   Gourraud, Pierre Antoine ^a   Zhu, Alyssa H ^a   Datta, Esha ^a   Schlaeger, Regina ^a,b   Caillier, Stacy J ^a   Santaniello, Adam ^a   Lizée, Antoine ^a   Himmelstein, Daniel S ^a,c   Baranzini, Sergio E ^a,c   Hollenbach, Jill ^a   Cree, Bruce A C ^a   Hauser, Stephen L ^a,c   Oksenberg, Jorge R ^a,c   Henry, Roland G ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CASE CONTROL STUDY; CERVICAL SPINAL CORD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GRAY MATTER; HAPLOTYPE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SPINAL CORD; WHITE MATTER; ALLELE; BRAIN; CAUCASIAN; DIAGNOSTIC IMAGING; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THREE DIMENSIONAL IMAGING; YOUNG ADULT;

HLA ANTIGEN CLASS 1;

ADULT; AGE OF ONSET; ALLELES; BRAIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SPINAL CORD; YOUNG ADULT;

EID: 84978141630     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.0980     Document Type: Article

References (35)

1. Hauser SL, Goodin DS. Multiple Sclerosis and other demyelinating diseases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw Hill; 2012:3395-3409.
2. Beecham AH, Patsopoulos NA, Xifara DK, et al; International Multiple Sclerosis Genetics Consortium (IMSGC);Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45 (11):1353-1360.
3. Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet. 2005;14(14):2019-2026.
4. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18): 2813-2824.
5. Moutsianas L, Jostins L, Beecham AH, et al; International IBD Genetics Consortium (IIBDGC); International Multiple Sclerosis Genetics Consortium. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2015; 47(10):1107-1113.
6. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000;48(2):211-219.
7. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000;178(2):132-135.
8. Hensiek AE, Sawcer SJ, Feakes R, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72(2):184-187.
9. Smestad C, Brynedal B, Jonasdottir G, et al. The impact of HLA-A and-DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol. 2007;14 (8):835-840.
10. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009;132(pt 1):250-259.
11. Fusco C, Andreone V, Coppola G, et al. HLA-DRB11501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology. 2001;57(11):1976-1979.
12. Tur C, Ramagopalan S, Altmann DR, et al. HLA-DRB115 influences the development of brain tissue damage in early PPMS. Neurology. 2014;83 (19):1712-1718.
13. Healy BC, LiguoriM, Tran D, et al. HLA B44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010;75(7): 634-640.
14. Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014;76(4):568-580.
15. Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol. 2015;72(8):897-904.
16. Gourraud PA, Khankhanian P, Cereb N, et al. HLA diversity in the 1000 Genomes dataset. PLoS One. 2014;9(7):e97282.
17. Field J, Browning SR, Johnson LJ, et al; Australia and New Zealand Multiple Sclerosis Genetics Consortium. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. PLoS One. 2010;5(10):e13454.
18. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1): 1-22.
19. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008; 358(26):2796-2803.
20. De Jager PL, Chibnik LB, Cui J, et al; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009;8(12):1111-1119.
21. Wei Z,Wang K, Qu HQ, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet. 2009;5(10):e1000678.
22. Gourraud PA, McElroy JP, Caillier SJ, et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol. 2011;69(1):65-74.
23. Isobe N, Damotte V, Lo Re V, et al. Genetic burden in multiple sclerosis families. Genes Immun. 2013;14(7):434-440.
24. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10): 903-912.
25. Kearney H,Miller DH, Ciccarelli O. Spinal cord MRI in multiple sclerosis-diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11(6): 327-338.
26. Sawcer S, Hellenthal G, Pirinen M, et al; International Multiple Sclerosis Genetics Consortium;Wellcome Trust Case Control Consortium Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
27. Harbo HF, Isobe N, Berg-Hansen P, et al. Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. Mult Scler. 2014;20(6):660-668.
28. Hilven K, Patsopoulos NA, Dubois B, Goris A. Burden of risk variants correlates with phenotype of multiple sclerosis. Mult Scler. 2015;21(13): 1670-1680.
29. Kikuchi S, Fukazawa T, NiinoM, et al. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands: human leukocyte antigen. Neurology. 2003;60(4):647-651.
30. Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun. 2015;64: 13-25.
31. Mühlau M, Buck D, Förschler A, et al. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler. 2013;19(11):1485-1492.
32. VercellinoM, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68(5): 489-502.
33. Cohen AB, Neema M, Arora A, et al. The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging. 2012;22(2): 122-128.
34. Jovicich J, Czanner S, Greve D, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30(2):436-443.
35. Thompson PM, Stein JL, Medland SE, et al; Alzheimer's Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014;8(2):153-182.